WASHINGTON--(BUSINESS WIRE)--The Biotechnology Industry Organization expressed disappointment on today’s vote in the House of Representatives on H.R. 4, the Medicare Prescription Drug Price Negotiation Act of 2007, and urged the Senate to oppose similar legislative efforts such as S. 250, the Medicare Enhancements for Needed Drugs Act of 2007.
